Table 1.
List of primary HPV screening strategies evaluated.
Fig 1.
Modelled screening pathways of (a) CP, (b) S1a, (c) S2a, (d) S3a and (e) S4a. Coloured boxes indicate variations in other sub-strategies assessed.
HG- High-grade (including ASC-H and HSIL); HR HPV– high risk HPV; LG –low-grade (including ASC-US and LSIL); Neg—Negative; OHR HPV- non-16/18 high -risk HPV
Table 2.
Selected key model parameter assumptions.
Table 3.
Model-predicted cervical cancer incidence, cervical cancer death, histologically-confirmed CIN2/3 and cost associated with screening program.
Fig 2.
Estimated age-specific of cervical cancer incidence rate and cervical cancer mortality rate for all strategies.
Fig 3.
Cost-effectiveness planes for (a) unvaccinated scenario and (b) vaccinated scenario.
Fig 4.
Model-predicted resource utilisation for all, assuming 2017 Australian female population.
Fig 5.
Model predicted average lifetime number of (a) screening/follow-up episodes and (b) number of colposcopies examinations.
Fig 6.
Comparison of the number of cervical cancer cases with the number of women who received treatment for precancer predicted for each strategy.
Numbers shown on the chart represent the number of additional treatments required per cancer case prevented compared to current practice. The number of additional treatments required per cancer case prevented ratio was calculated for each strategy with a higher number precancer treatments and lower number of cervical cancer cases than CP. The calculated ratio is display in the figure on side of the marker that represents the strategy.